Editors:
- Outlines strategies and methodologies designed to guide pharmaceutical and biotechnology companies through the drug discovery and development process
- Emphasis on advancing higher quality drug candidates into preclinical and clinical development, resulting in more efficacious and safer drugs
Part of the book series: Biotechnology: Pharmaceutical Aspects (PHARMASP, volume IV)
Buy it now
Buying options
Tax calculation will be finalised at checkout
Other ways to access
This is a preview of subscription content, log in via an institution to check for access.
Table of contents (18 chapters)
-
Front Matter
-
Back Matter
About this book
Editors and Affiliations
-
University of Kansas, Lawrence, USA
Ronald T. Borchardt
-
Wyeth Research, Monmouth Junction, USA
Edward H. Kerns
-
Pfizer, Inc., Kalamazoo, USA
Michael J. Hageman
-
University of North Carolina, Chapel Hill, USA
Dhiren R. Thakker
-
Eli Lilly Research Laboratory, Greenfield, USA
James L. Stevens
Bibliographic Information
Book Title: Optimizing the "Drug-Like" Properties of Leads in Drug Discovery
Editors: Ronald T. Borchardt, Edward H. Kerns, Michael J. Hageman, Dhiren R. Thakker, James L. Stevens
Series Title: Biotechnology: Pharmaceutical Aspects
DOI: https://doi.org/10.1007/978-0-387-44961-6
Publisher: Springer New York, NY
eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)
Copyright Information: Springer-Verlag New York 2006
Hardcover ISBN: 978-0-387-34056-2Published: 03 August 2006
Softcover ISBN: 978-1-4939-5047-8Published: 25 October 2016
eBook ISBN: 978-0-387-44961-6Published: 31 December 2007
Edition Number: 1
Number of Pages: X, 512
Topics: Pharmacology/Toxicology